The plan is to commence treatment with DA+myelotarg
Cytogenetic and molecular studies show
t(8:21)
C-KIT positive
FLT3 negative
NPM1 negative
Would this change your management?
How are you going to monitor response in this patient?
The plan is to commence treatment with DA+myelotarg
Cytogenetic and molecular studies show
t(8:21)
C-KIT positive
FLT3 negative
NPM1 negative
Would this change your management?
How are you going to monitor response in this patient?